Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Fentanyl inhalation - Boehringer Ingelheim Canada

Next Previous
Drug Profile

Fentanyl inhalation - Boehringer Ingelheim Canada

Alternative Names: Inhaled fentanyl - Boehringer Ingelheim Canada; Nebulized Fentanyl - Boehringer Ingelheim Canada; Nebulized fentanyl citrate - Boehringer Ingelheim Canada

Latest Information Update: 22 Jul 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Boehringer Ingelheim (Canada)
  • Developer Boehringer Ingelheim (Canada); Queens University
  • Class Amides; Benzene derivatives; General anaesthetics; Opioid analgesics; Piperidines; Small molecules
  • Mechanism of Action Opioid mu receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Dyspnoea

Most Recent Events

  • 22 Jul 2024 Discontinued - Phase-III for Dyspnoea in Canada (Inhalation)
  • 25 Sep 2020 Fentanyl inhalation is still in phase III trials for Dyspnoea in Canada (NCT03018756)
  • 16 Sep 2020 Queens University and Boehringer Ingelheim Canada temporarily suspend a phase III trial for Dyspnoea in Canada due to COVID-19 pandemic (NCT03018756)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top